About Us
Our
Medicines
- YCANTH
Product
Candidates
Investors &
Media
Careers

Menu

About Us
Our
Medicines
- YCANTH
Product
Candidates
Investors &
Media
Careers

Breaking News:
Verrica announced the approval of YCANTH™ (cantharidin) topical solution 0.7%

January 15 – 24, 2021 – Winter Clinical Dermatology Conference (Virtual)

About Us

Our Company
Leadership
Compliance
Contact
Medical Education Grants

Our Medicines

YCANTH

Product Candidates

Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications

Investors & Media

Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection

Careers

Terms of Use
Privacy Policy
Patent Notices

Twitter Linkedin-in Facebook-f

© 2023 Verrica Pharmaceuticals.

VIRTUAL KOL EVENT

Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum

October 11th, 2023 | 11:00 AM ET

Click to Register & Attend